Peter Langmuir

Trials

Studies that name Peter Langmuir as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:44 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04949191 · The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

  Incyte Corporation · terminated · Advanced Malignancies · study director
• Ph2
  NCT04071366 · A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

  Incyte Corporation · completed · Cytokine Release Syndrome · study director
• Ph2
  NCT03822117 · Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  Incyte Corporation · terminated · Solid Tumor Malignancy · study director
• Ph3
  NCT03656536 · A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

  Incyte Corporation · terminated · Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma · study director
• Ph1
  NCT03424122 · INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

  Incyte Corporation · completed · B-cell Lymphoma · study director
• Ph2
  NCT03144687 · A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

  Incyte Corporation · completed · MPN (Myeloproliferative Neoplasms) · study director
• Ph2
  NCT02955940 · An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

  Incyte Corporation · active not recruiting · Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer · study director
• Ph1/Ph2
  NCT02917993 · An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

  Incyte Corporation · completed · Lung Cancer · study director
• Ph1/Ph2
  NCT02760485 · A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  Incyte Corporation · completed · Lymphoma · study director
• Ph2
  NCT02456675 · INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

  Incyte Corporation · terminated · Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma · study director
• Ph1
  NCT01905813 · Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

  Incyte Corporation · completed · B-cell Malignancies · study director
• Ph2
  NCT01348490 · Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

  Incyte Corporation · completed · MPN (Myeloproliferative Neoplasms) · study director
• Ph1
  NCT00937664 · Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

  AstraZeneca · terminated · Cancer, Solid Tumors, Advanced Solid Malignancies · study director
• Ph1
  NCT00473616 · Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

  AstraZeneca · terminated · Advanced Solid Tumors, Cancer, Advanced Solid Malignancies · study director
• Ph1
  NCT00413686 · Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

  AstraZeneca · completed · Solid Tumors · study director
• Ph2
  NCT00378482 · A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

  AstraZeneca · completed · Colorectal Neoplasms, Melanoma, Prostatic Neoplasms · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 04:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.